Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|May 5, 2017
High Cost Drug Launches in Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Sheila Arquette, RPh, director of pharmacy services at Independent Health, discusses the lessons of high cost drugs such as PCSK9 inhibitors on specialty pharmacy.
Advertisement
Sheila Arquette, RPh, director of pharmacy services at Independent Health, discusses the lessons of high cost drugs such as PCSK9 inhibitors on specialty pharmacy.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
3
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5